Iq-ai Share Discussion Threads

[joeblogg2] 31/5/2022 08:59

Pity TB does not promote the company, IB getting on with business will soon interest majors!!!

[festario] 31/5/2022 08:58

It shows a serious intent, plus it demonstrates a professional approach.

[clocktower] 31/5/2022 08:48

Hopefully the start of more good news.

[bad gateway] 31/5/2022 08:47

Good to hear they're applying for their 510.
Doesn't sound from the FDA's page that there'll be a great issue with it as from current news there's an obvious demand growing for an alternative to gadolinium.

[bad gateway] 19/5/2022 14:04

re the "current situation"

IQ-AI - Imaging Biometrics
@IQAI_IB
In discussions with a few sites who are considering IB Neuro's quantitative MR maps as an alternative to the on-going shortage of iodinated contrast media. Contact: [e-mail].

Statement from the ACR Committee on Drugs and Contrast Media.. (linking to spurs link above)

[spurs90] 14/5/2022 12:30

This current situation goes massively in iqai’s favour. Would be good to see IB zero gad fast tacked through the fda process to help with this problem.

Updated May 13, 2022

The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media. The following statement offers some recommendations on how providers may address this emergency locally. The recommendations are not exhaustive or prescriptive. They are intended as a resource for imaging providers and their institutions to continue to provide high-quality patient care during times of shortage of contrast media. Providers and administrative leaders are encouraged to incorporate sound clinical judgment in all decisions affecting patient care.

The ACR recognizes that this is a rapidly evolving situation. Guidance may be revised as circumstances continue to change.

Practices with questions regarding the GE contrast media shortage are encouraged to contact their local GE diagnostic pharmaceutical representative who will have the most current information.

[bad gateway] 10/5/2022 12:45

Has been a bit of a slow start with this one.
On the bright side they've heard of the cancer trial even in Nigeria.



Its just the market that's blissfully unaware.

[festario] 10/5/2022 11:13

It's going to Hell in a handcart this.Worst decision of my investing life was failing to sell this on the spike to 20p

[rock star] 06/5/2022 10:43

Sell in May and go away. As we head towards a global recession difficult to get to excited. Sept/Oct might be market bottom.

Revenue increase and reduced loss were better than hoped so promising. Got going concern tick from the TB loan facility.

[clocktower] 05/5/2022 10:51

The number of posters rising is an interesting feature of this thread Festario. It might not yet have attracted those with deep pockets at this level but I suspect that it will before very long.

Then expect another TB.

[festario] 04/5/2022 10:37

News like yesterday's would ordinarily add 50 to 100% to the share price of a micro cap company.All I can think is, the market has heard it all before from Trevor, and they simply don't believe the story.

[joeblogg2] 03/5/2022 14:51

iqai completely ignored by the market and investors but hopefully not for long as it builds incredible life saving technology!!!

[festario] 03/5/2022 14:48

Now, we need to hope that someone wants to pay for it.

[wapper] 03/5/2022 14:44

Excellent RNS indeed

[festario] 03/5/2022 14:35

Nice RNS.... validation of IB neuro imaging in tumour distinction, where others failed.

[festario] 01/5/2022 09:44

Happy with £500k total revenue, but nearly £1 million in 'administrative costs' are you?Fair enough.

[bad gateway] 28/4/2022 21:49

Odd time for results but happy with them all the same and very pleased with doubled revenue for the year.

Looking forward to the trial still. Believe in the last interview they told us that if proven therapeutic they won't take patients off GaM after and today have told us they'll be looking for the same favourable results in humans as in animal studies.
"If" they shrink glioblastoma cells in human trials could be a very interesting year for them.

"At the time of writing, all necessary approvals have been obtained and the trial is open for enrolment. While the primary aim of Phase I trials is to determine safe dosing levels for Phase II, we will be closely monitoring the response of these patients to the agent using our imaging technology. Our hope for Phase 1 is that we see the encouraging results in human subjects that were demonstrated in the pre-clinical study. Upon receiving positive feedback from the Phase I, we plan to continue to develop GaM with the aspiration to improve prognosis for patients suffering this disease."



"Last April 2021, we announced the sponsorship of a Phase I clinical trial. The trial follows a successful pre-clinical study that showed that the potential therapeutic compound Gallium Maltolate (GaM) shrunk glioblastoma (GBM) cells in animal models. In June 2021, the FDA approved the investigational new drug (IND) application for GaM and the treatment of the most aggressive form of brain cancer, GBM, and the first-in-human trial of an oral form of GaM has now commenced in the USA."


Back to sleep mode til they do.

[festario] 28/4/2022 19:14

There always is.... Revenue is up a big percentage, but still a very small number considering these major medical centres supposedly beating a path to our door.

[spurs90] 28/4/2022 18:45

Major Highlights
· Early in 2021, we aligned and focused resources to accelerate the development of IB Zero G™, the Artificial Intelligence (AI) model for generating simulated "with contrast" images using non-contrast (0% gadolinium) images as input. The effort included the labelling of many datasets necessary to be used to perfect the AI model. Sufficient progress was made throughout the year and a 510(k) application to the US FDA is in now in preparation with submission for approval anticipated in May '22.

· Last April 2021, we announced the sponsorship of a Phase I clinical trial. The trial follows a successful pre-clinical study that showed that the potential therapeutic compound Gallium Maltolate (GaM) shrunk glioblastoma (GBM) cells in animal models. In June 2021, the FDA approved the investigational new drug (IND) application for GaM and the treatment of the most aggressive form of brain cancer, GBM, and the first-in-human trial of an oral form of GaM has now commenced in the USA.
· In April 2021, a $3 million grant was awarded in collaboration with Professor Kathleen Schmainda, PhD, from the Medical College of Wisconsin (MCW). The National Institutes of Health (NIH)-funded grant will be used to validate and translate an AI model that can detect infiltrating tumour cells before they are visible on standard imaging. This would represent the ultimate in early detection.
· In June 2021, we were awarded a US patent for the AI technology contained in IB Zero G™. This 0% contrast media dose approach has the potential of offering remarkable benefits which include a more comfortable patient experience, more productive radiology departments, and reduced risks associated from the long-term, albeit uncertain, side effects of repeated GBCA use.
· In September 2021, we received a European patent for IB's "dual-echo" technology. Previously patented in the US, this technology combines MR scanner data acquisition and post-processing to generate two unique sets of data that currently require two independent MR exams. In addition, the technology eliminates the need for the commonly accepted "pre-load" dose of gadolinium-based contrast agent and minimizes other imaging artefacts inherent with this type of imaging. The advancement of this technology is being done in collaboration with the Barrow Neurological Institute under a funded NIH grant. An additional aim of the grant is to harmonize this approach across all major scanner platforms.
· In November 2021, MD Anderson Cancer Centre (University of Texas, Houston) adopted IB Clinic - container edition. MD Anderson is consistently ranked as the #1 cancer centre in the USA and is a recognized leader in using cutting edge technologies in an attempt to improve patient outcomes. This installation again underscores the significance of the automated and quantitative capability of IB Clinic - container edition.

Lots to look forward to!

[festario] 28/4/2022 18:42

Results RNS out, at nearly 6pm

[festario] 27/4/2022 14:27

Latest IQAI share price is more pertinent. They have less Twitter followers than my own piddly website.It's really gained zero interest or any kind of traction in the last 3 years.